Literature DB >> 6761868

The anticancer spectrum of ifosfamide.

H L Hunter, E F Harrison.   

Abstract

Mesh：

Substances：

Year:  1982        PMID： 6761868

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  12 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.

Authors:  C Manegold; P Worst; J Bickel; H Schmid; P Drings; M Kaufmann
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity.

Authors:  D M Nanus; D P Kelsen; R Lipperman; M Eisenberger
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

Review 5.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

6.  Ifosfamide combination chemotherapy in advanced breast cancer.

Authors:  H Schmid; M Kaufmann; E M Grischke; G Bastert
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  A phase II study of ifosfamide in endometrial cancer.

Authors:  C Barton; E J Buxton; G Blackledge; J J Mould; C A Meanwell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.

Authors:  I Magrath; J Sandlund; A Raynor; S Rosenberg; V Arasi; J Miser
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.

Authors:  L H Einhorn
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.

Authors:  R E Coleman; P G Harper; C Gallagher; R Osborne; E M Rankin; A C Silverstone; M L Slevin; R L Souhami; J S Tobias; C W Trask
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.